ATE496041T1 - 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel - Google Patents

2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel

Info

Publication number
ATE496041T1
ATE496041T1 AT06753758T AT06753758T ATE496041T1 AT E496041 T1 ATE496041 T1 AT E496041T1 AT 06753758 T AT06753758 T AT 06753758T AT 06753758 T AT06753758 T AT 06753758T AT E496041 T1 ATE496041 T1 AT E496041T1
Authority
AT
Austria
Prior art keywords
production
medicinal products
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
AT06753758T
Other languages
English (en)
Inventor
Benjamin Perry
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511781A external-priority patent/GB0511781D0/en
Priority claimed from GB0600213A external-priority patent/GB0600213D0/en
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE496041T1 publication Critical patent/ATE496041T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06753758T 2005-06-09 2006-05-22 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel ATE496041T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0511781A GB0511781D0 (en) 2005-06-09 2005-06-09 2,6-quinolinyl derivatives, processes for preparing them and their uses
US20615805A 2005-08-18 2005-08-18
GB0600213A GB0600213D0 (en) 2006-01-06 2006-01-06 2,6-quinolinyl derivatives, processes for preparing them and their uses
PCT/EP2006/004811 WO2006131200A1 (en) 2005-06-09 2006-05-22 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament

Publications (1)

Publication Number Publication Date
ATE496041T1 true ATE496041T1 (de) 2011-02-15

Family

ID=36968449

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06753758T ATE496041T1 (de) 2005-06-09 2006-05-22 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel

Country Status (19)

Country Link
US (1) US7732614B2 (de)
EP (1) EP1902045B1 (de)
JP (1) JP2008542407A (de)
KR (1) KR20080021085A (de)
AR (1) AR054129A1 (de)
AT (1) ATE496041T1 (de)
AU (1) AU2006254772B2 (de)
BR (1) BRPI0611243A2 (de)
CA (1) CA2610800A1 (de)
DE (1) DE602006019731D1 (de)
EA (1) EA013080B1 (de)
IL (1) IL187235A0 (de)
MX (1) MX2007014721A (de)
MY (1) MY140739A (de)
NO (1) NO20080125L (de)
NZ (1) NZ563739A (de)
PE (1) PE20070081A1 (de)
TW (1) TW200716605A (de)
WO (1) WO2006131200A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649842A (zh) 2002-04-30 2005-08-03 Ucb公司 2,6－喹啉基和2,6－萘基衍生物、用于制备它们的方法和它们作为vla－4抑制剂的用途
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN103169965A (zh) * 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 治疗多发性硬化
JP2008542407A (ja) 2005-06-09 2008-11-27 ユセベ ファルマ ソシエテ アノニム ２，６キノリニル誘導体、それらを調製するための方法及び薬剤としてのそれらの使用
WO2008125215A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
MX2011010971A (es) * 2009-04-17 2012-01-19 Biogen Idec Inc Composiciones y metodos para tratar leucemia mielogena aguda.
AU2011239512B2 (en) 2010-04-16 2016-01-21 Biogen Ma Inc. Anti-VLA-4 antibodies
MY160723A (en) * 2013-12-30 2017-03-15 Univ Putra Malaysia An anticoagulant
USD812958S1 (en) 2016-06-08 2018-03-20 Samsung Electronics Co., Ltd. Cooktop
WO2019200202A1 (en) 2018-04-12 2019-10-17 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
WO2020092375A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN112969504B (zh) * 2018-10-30 2024-04-09 吉利德科学公司 用于抑制α4β7整合素的化合物
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin
CA3154269A1 (en) 2019-10-16 2021-04-22 Matthew G. Bursavich Inhibiting human integrin .alpha.4.beta.7

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018606A1 (fr) 1994-12-14 1996-06-20 Santen Pharmaceutical Co., Ltd. Nouveaux derives 1,3-dialkyluree
CA2301377C (en) 1997-08-22 2009-10-06 F. Hoffmann-La Roche Ag N-aroylphenylalanine derivatives
KR20010085630A (ko) 1998-08-26 2001-09-07 앤드류 앵뉴 세포 접착 억제를 조절하는 아자-비사이클
EP1175412A1 (de) 1999-04-28 2002-01-30 Dr. Reddy's Research Foundation Substituierte bicyclische heterocycle, verfahren zu ihrer herstellung und ihre verwendung als mittel gegen fettsucht und cholesterol
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
CN1649842A (zh) * 2002-04-30 2005-08-03 Ucb公司 2,6－喹啉基和2,6－萘基衍生物、用于制备它们的方法和它们作为vla－4抑制剂的用途
US7153870B2 (en) * 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0329584D0 (en) 2003-12-20 2004-01-28 Tanabe Seiyaku Co Novel compounds
JP2008542407A (ja) 2005-06-09 2008-11-27 ユセベ ファルマ ソシエテ アノニム ２，６キノリニル誘導体、それらを調製するための方法及び薬剤としてのそれらの使用

Also Published As

Publication number Publication date
NO20080125L (no) 2008-01-08
MX2007014721A (es) 2008-02-14
US20070004775A1 (en) 2007-01-04
EA013080B1 (ru) 2010-02-26
AU2006254772A1 (en) 2006-12-14
EP1902045B1 (de) 2011-01-19
BRPI0611243A2 (pt) 2010-08-24
NZ563739A (en) 2009-12-24
JP2008542407A (ja) 2008-11-27
AU2006254772B2 (en) 2011-06-02
WO2006131200A1 (en) 2006-12-14
CA2610800A1 (en) 2006-12-14
EP1902045A1 (de) 2008-03-26
EA200702589A1 (ru) 2008-06-30
PE20070081A1 (es) 2007-02-15
US7732614B2 (en) 2010-06-08
AR054129A1 (es) 2007-06-06
MY140739A (en) 2010-01-15
DE602006019731D1 (de) 2011-03-03
KR20080021085A (ko) 2008-03-06
TW200716605A (en) 2007-05-01
IL187235A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
ATE496041T1 (de) 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel
ATE496919T1 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
ATE441638T1 (de) 4,5-diphenyl-pyrimidinyl substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE438645T1 (de) 7-phenylamino-4-chinolon-3-carbonsäure-derivate verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE490256T1 (de) Neue cyanopyrrolidide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE381564T1 (de) Arylsubstituierte polycyclische amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE437868T1 (de) Ausgewahlte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE502005009723D1 (de) Arylsubstituierte heterozyklen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE478066T1 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
ATE332898T1 (de) Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
ATE394392T1 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE602005015027D1 (de) Glucocorticoid-mimetika, verfahren zu deren herstellung, pharmazeutische zusammensetzungen und deren verwendung
ATE302754T1 (de) Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE299880T1 (de) Neue fluorencarbonsaureester, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
ATE537167T1 (de) Phenyl- und pyridyl-i, 2 , 4 -oxadiazolon- derivate mit phenylgruppe, verfahren zu deren darstellung und deren verwendung als arzneimittel
ATE348609T1 (de) Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
ATE460401T1 (de) 1,2,4,5-tetrahydro-3h-benzazepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE344034T1 (de) N-adamantylmethyl-derivate und zwischenprodukte als pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
DE602005018911D1 (de) 1,4-Dihydropyridine-kondensierte Heterocyclen Verfahren zu deren Herstellung sowie Verwendung und Zusammensetzungen dergleichen
DE112006003526A5 (de) Carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung
ATE482193T1 (de) Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen
ATE517092T1 (de) Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
ATE384069T1 (de) Alkyliden-tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
ATE372992T1 (de) Indanyl-piperazinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE487706T1 (de) Cyclische n-ä1,3,4ü-thiadiazol-2-yl- benzsulfonamide, verfahren zu deren herstellung und deren verwendung als arzneimittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties